Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Ryman Healthcare (RYM) / FY22

Reported NPAT jumped 63.8% but underlying profit grew only 13.6%

Investment property revaluations drove the headline gain while capex at 55.9% of revenue absorbed most of the operating cash flow expansion.

Healthcare / Retirement living

RYM metric context

Comparable chart history for this briefing.

Not enough chartable history yet. This panel will populate as comparable periods are published.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 12 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$2.3b

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

Not available

i

Not meaningful when recent earnings are negative.

EPS

-0.17

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

44.25x

i

Enterprise value compared with recent EBITDA.

P/FCF

12.41x

i

Market cap compared with recent free cash flow.

P/B

0.57x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
17 June 2022
Published
29 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

FY22 vs FY21

Revenue

$508.8m

+11.6% ↑ vs $455.8m

Net profit after tax

$692.9m

+63.8% ↑ vs $423.1m

Net cash inflow from operating activities

$586m

+41.8% ↑ vs $413.1m

Profit before tax

$722.1m

+75.9% ↑ vs $410.5m

Cash and cash equivalents

$28.3m

+40.3% ↑ vs $20.2m

Total assets

$11b

+19.6% ↑ vs $9.2b

What changed

Reported net profit after tax rose 63.8% to $692.9m and profit before tax rose 75.9% to $722.1m, but the company's preferred underlying profit measure (which strips out unrealised investment property revaluations) grew only 13.6% per the release commentary

That gap is the most material feature of the result: revenue grew 11.6% to $508.8m, which is much closer to the underlying earnings shape than the IFRS headline.

Operating cash flow rose 41.8% to $586.0m, helped by new sales and resales activity. However, capex stepped up 29.6% to $284.3m, lifting capex intensity to 55.9% of revenue. Gross borrowings rose 13.3% to $2.6b and trade debtors rose 31.3% to $654.8m, well ahead of revenue growth. Australia's revenue share rose to 14.4% from 11.1% as that segment grew 45.8%.

What matters

Underlying versus reported profit

The 63.8% NPAT print is dominated by non-cash fair-value movements on investment property, not operating performance. The disclosed underlying profit growth of 13.6% is the cleaner read on the business, and that figure sits broadly in line with revenue growth of 11.6%. Anchoring on the reported number overstates the rate of operating improvement materially.

Capital intensity is rising, not falling. Capex of $284.3m equals 55.9% of revenue, up from 48.1% prior, and free cash flow pre-lease of $301.7m covers only 43.5% of reported NPAT. The business is in heavy build-out mode, funded by a combination of internal cash, resales, and incremental borrowings of roughly $302m. This matters because reported earnings include large unrealised gains that cannot fund the build programme.

Receivables ballooned faster than revenue. Trade debtors rose 31.3% to $654.8m against 11.6% revenue growth, lifting receivable days to 469.7 from 399.3. For a retirement village operator a large receivable balance is structural (occupation-right balances and resale-related amounts), but the rate of growth still warrants attention because it ties up incremental working capital and limits headline cash conversion.

Expectations

No stated financial targets were supplied in the release context, so the result has to be read on its own

The HY22 interim disclosed first-half NPAT of $281.5m, which is 40.6% of the full-year reported figure, implying an H2-weighted earnings shape — consistent with valuation-driven profits crystallising at year end rather than a step-up in underlying trading. Revenue was more evenly split (48.7% in H1), reinforcing that the H2 skew is largely a fair-value phenomenon.

The result does support continued top-line growth at low double-digit rates and material expansion in Australia, but it does not provide forward work or development pipeline data that would let an outside reader test the durability of the build programme behind the rising capex.

Quality of result

Result quality is mixed and depends heavily on which earnings number is used

Underlying profit growth of 13.6% is broadly cash-relevant and matches the revenue and operating cash flow direction. The reported +63.8% NPAT is not — it is driven by unrealised property revaluations and is amplified by a negative effective tax rate of -4.0% (versus -3.1% prior), so PBT growth at +75.9% actually exceeded NPAT growth.

The cash side is genuine but consumed by reinvestment. Operating cash flow of $586.0m is strong, but pre-lease free cash flow of $301.7m has to absorb a $302.6m increase in gross borrowings to keep the development programme funded. Equity rose 21.4% and ROE improved to 20.2% from 14.9%, but that ROE benefits from the same revaluation gains driving the NPAT line; the underlying return on capital deployed in operations is materially lower.

Unresolved

Open questions

What is the expected trajectory of capex intensity over the next two to three years, and at what point does free cash flow cover both maintenance capex and dividends?
How much of the 31.3% increase in trade debtors is occupation-right related versus genuine collection delay, and what is the duration profile of that balance?
What underlying profit growth rate does management expect now that the Australian segment is 14.4% of revenue and growing 45.8% year on year?
How does management intend to manage gross borrowings of $2,576.7m given the rising capex commitment and the H2-weighted reliance on valuation gains for reported earnings?
Why does the effective tax rate remain negative at -4.0%, and what should an investor model for normalised tax in future years?

This briefing cannot assess the development pipeline economics, embedded value of the deferred management fee receivable, or the sustainability of the property revaluation assumptions because none of those disclosures were supplied in the source extracts.

Chat

Ask about RYM FY22

Ask follow-up questions about Ryman Healthcare's FY22 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about RYM FY22

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Ryman Healthcare's FY22 result.

What is the expected trajectory of capex intensity over the next two to three years, and at what point does free cash flow cover both maintenance capex and dividends?Why does "Underlying versus reported profit" matter?How strong was the cash and earnings quality in FY22?What should I watch next for RYM after FY22?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Ryman Healthcare Limited - Annual Report 2022

FY22 / financial report↗

Prior comparable period

Ryman Healthcare Limited - Annual Report 2021

FY21 / financial report↗

Interim context

Ryman Healthcare Limited - Announcement Numbers - 30 September 2021

HY22 / financial report↗

Ryman Healthcare Limited - Media Release and Key Statistics - 30 September 2021

HY22 / media release↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 12.1pp, with a distortion flag in the result.

→

Revenue growth context

Revenue growth was 11.6% for this reporting period.

→

ROE and capital efficiency

ROE was 20.2%, +5.3pp versus the prior comparable period.

→

Working-capital pressure

Inventory days were 19 days, -2 days versus the prior comparable period.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when RYM publishes next

Get the next Ryman Healthcare briefing and related NZX reporting-season updates by email.